AstraZeneca and Moderna Therapeutics announce exclusive agreement
21 March 2013 | By AstraZeneca
Agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer...
List view / Grid view
News
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
21 March 2013 | By Novartis
New data presented...
AstraZeneca outlines strategy to return to growth and achieve scientific leadership
21 March 2013 | By AstraZeneca
AstraZeneca will outline its strategy to return to growth and achieve scientific leadership...
3rd Annual Dissolution Symposium on June 3-4 2013
20 March 2013 | By Sirius Analytical Instruments Ltd
The University of Bath, Department of Pharmacy and Sirius Analytical invite you to attend the 3rd Annual Dissolution Symposium...
New data show Azilect® provided clinical benefit in patients with early Parkinson’s
20 March 2013 | By H. Lundbeck A/S
Results add to evidence for Azilect as an effective and well-tolerated treatment option at different stages of the progression of PD...
Positive year one results from Biogen Idec Phase 3 ADVANCE trial of PLEGRIDY™ presented at AAN Meeting
20 March 2013 | By Biogen Idec
“These full first-year results provide a more complete picture of PLEGRIDY..."
FDA Advisory Committee votes favorably on Abbott’s minimally invasive MitraClip® device for patients with significant mitral regurgitation who are too high risk for surgery
20 March 2013 | By Abbott
"We appreciate the FDA's dedication of time and resources..."
Boehringer Ingelheim and Lilly initiate MARLINA™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria
19 March 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company announced today the initiation of a Phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albuminuria, and urinary albumin-to-creatinine (UACR) ratio 30-3000 mg/g creatinine, in addition to current standard therapy for diabetic nephropathy.…
Real world study comparing commonly prescribed COPD medicines shows choice of treatment has impact on patient outcomes
19 March 2013 | By AstraZeneca
PATHOS a real-world retrospective study...
US Patent Office grants patent claiming dosing regimen for TECFIDERA™ (dimethyl fumarate)
19 March 2013 | By Biogen Idec
Patent offers protection until 2028 and strengthens growing product patent portfolio...
Amgen announces top-line results of Phase 3 talimogene laherparepvec trial in melanoma
19 March 2013 | By Amgen
These are the first Phase 3 results of this novel approach to cancer therapy...
Collaboration to accelerate drug discovery in cardiac disease announced
19 March 2013 | By InvivoSciences Inc.
Torrey Pines Institute for Molecular Studies and InvivoSciences collaborate to accelerate drug discovery in cardiac disease...
AstraZeneca to establish strategic R&D centres to enhance innovation and pipeline productivity
18 March 2013 | By AstraZeneca
Centres positioned to take better advantage of bioscience clusters...
Alcon announces EU approval of Jetrea®
18 March 2013 | By Novartis
Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole...
Roche’s Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older
18 March 2013 | By Roche
The EMA has expanded the approval of Pegasys...
